Estimating the potential health economic value of introducing universal opt-out testing for HIV in emergency departments in Italy

Abstract In Italy, an estimated 13 000–15 000 people have undiagnosed HIV, and in 2020, 60% of new diagnoses were late-stage (CD4 < 350 cells/mm3). In hospitals, including emergency departments (EDs), testing is largely limited to indicator-condition-guided testing (IC), with written consent univ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of public health Jg. 35; H. 5; S. 999 - 1006
Hauptverfasser: d’Arminio Monforte, Antonella, d’Ettorre, Gabriella, Galardo, Gioacchino, Lani, Enyal, Kagenaar, Eva, Huntington, Susie, Jarrett, James, Ruf, Murad, Ricciardi, Walter
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Oxford University Press 01.10.2025
Schlagworte:
Adult
CD4 antigen
Clinical outcomes
Cost analysis
Cost effectiveness
Cost-Benefit Analysis
Costs
Data
Decision making
Decision Trees
Economic models
Economics
Emergency medical care
Emergency medical services
Emergency Service, Hospital - economics
Emergency Service, Hospital - statistics & numerical data
Emergency services
Female
Health care expenditures
Health information
Health services
Health status
HIV
HIV Infections - diagnosis
HIV Infections - economics
HIV Infections - epidemiology
HIV Testing - economics
Hospitals
Human immunodeficiency virus
Humans
Immune response
Italy - epidemiology
Male
Markov analysis
Markov Chains
Mass Screening - economics
Medical tests
Middle Aged
Patients
Public health
Quality adjusted life years
Tests
Thresholds
Undiagnosed
Value
Willingness to pay
Italy
ISSN:1101-1262, 1464-360X, 1464-360X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract In Italy, an estimated 13 000–15 000 people have undiagnosed HIV, and in 2020, 60% of new diagnoses were late-stage (CD4 < 350 cells/mm3). In hospitals, including emergency departments (EDs), testing is largely limited to indicator-condition-guided testing (IC), with written consent universally required. We developed a closed-cohort hybrid decision tree–Markov model to compare health economic values of two HIV testing strategies in the ED: (1) universal opt-out and (2) IC (Italian standard of care). Data sources included healthcare costs and HIV public health data, obtained from national reports and published studies. A lifetime time horizon and a National Health Service perspective were used. Primary outcomes were life years, quality-adjusted life years (QALYs), and costs. Universal opt-out testing resulted in better health outcomes at higher costs. For every 10 000 individuals attending ED, opt-out testing resulted in 15.78 additional new HIV diagnoses and 14.47 more people linked to HIV care compared with IC. Prevalence threshold analysis demonstrated that opt-out testing was cost-effective compared to IC when the HIV prevalence was 0.25% or higher, assuming a willingness-to-pay threshold of €30 000/QALY. Universal opt-out HIV testing in the ED could be a cost-effective way to increase the number of new HIV diagnoses and improve HIV health outcomes in Italy. The model may underestimate the full benefits of this strategy as our model did not consider disengaged patients or transmissions averted. Further research using real-world data is needed to verify our findings.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1101-1262
1464-360X
1464-360X
DOI:10.1093/eurpub/ckaf057